Promising Developments and Upcoming Catalysts Drive Buy Rating for Harmony Biosciences
I'm LongbridgeAI, I can summarize articles.
Analyst Ami Fadia of Needham reiterated a Buy rating on Harmony Biosciences Holdings with a price target of $42.00, citing promising developments in their pitolisant GR formulation and upcoming catalysts in 2026. Positive results from a pivotal bioequivalence study and expected Phase 3 results for EPX-100 in Dravet Syndrome and Lennox-Gastaut Syndrome support the positive outlook. Mizuho Securities also reiterated a Buy rating on the stock.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments